Arrowpoint Investment Partners (Singapore) Pte. Ltd. Madrigal Pharmaceuticals, Inc. Transaction History
Arrowpoint Investment Partners (Singapore) Pte. Ltd.
- $100 Billion
- Q3 2025
A detailed history of Arrowpoint Investment Partners (Singapore) Pte. Ltd. transactions in Madrigal Pharmaceuticals, Inc. stock. As of the latest transaction made, Arrowpoint Investment Partners (Singapore) Pte. Ltd. holds 792 shares of MDGL stock, worth $419,134. This represents 0.36% of its overall portfolio holdings.
Number of Shares
792Holding current value
$419,134% of portfolio
0.36%Shares
1 transactions
Others Institutions Holding MDGL
# of Institutions
408Shares Held
23.1MCall Options Held
666KPut Options Held
514K-
Baker Bros. Advisors LP New York, NY2.14MShares$1.13 Billion8.0% of portfolio
-
Rtw Investments, LP New York, NY1.99MShares$1.06 Billion12.22% of portfolio
-
John Paulson Paulson & Co. Inc. | New York, Ny1.91MShares$1.01 Billion31.28% of portfolio
-
Janus Henderson Group PLC London, X01.84MShares$975 Million0.41% of portfolio
-
Avoro Capital Advisors LLC New York, NY1.83MShares$970 Million11.49% of portfolio
About MADRIGAL PHARMACEUTICALS, INC.
- Ticker MDGL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 17,103,400
- Market Cap $9.05B
- Description
- Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III c...